Nemedan (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors, blocking excessive calcium entry caused by overstimulation with glutamate. This reduces excitotoxic neuronal injury, which is thought to contribute to the cognitive decline seen in Alzheimer’s disease.

The dosing regimen for Nemedan is determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Healthcare professionals follow approved guidelines to titrate the dose safely.

Safety data for memantine in pregnancy and lactation are limited. It is classified as a pregnancy category with unknown risk, so clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To request Nemedan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nemedan (memantine) belongs to the NMDA receptor antagonist class, differing from cholinesterase inhibitors such as donepezil. While cholinesterase inhibitors increase acetylcholine levels, memantine reduces glutamate‑mediated excitotoxicity. Both classes may be used together for additive symptomatic benefit in certain patients.

Nemedan should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability throughout its shelf life.

Nemedan is taken orally, usually as a tablet, with or without food. The exact administration schedule is set by the prescriber, who may start with a low dose and gradually increase it to the target therapeutic level.

Serious risks include seizures, severe allergic reactions, hallucinations, and cardiac arrhythmias. Patients should be monitored for these events, especially during dose titration or when taking interacting medications.

Nemedan is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists.